# Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

> **NCT00065572** · PHASE2 · SUSPENDED · sponsor: **AstraZeneca**

## Conditions studied

- Carcinoma, Renal Cell
- Kidney Neoplasms

## Interventions

- **DRUG:** ZD6126
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00065572
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2003-08
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** — (—)
- **Last updated:** 2011-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00065572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00065572, "Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00065572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*